FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Lamond David 		2. Issuer Name and Ticker or Trading Symbol

Cortexyme, Inc. [ CRTX ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

C/O CORTEXYME, INC., 269 EAST GRAND AVE. 		3. Date of Earliest Transaction (MM/DD/YYYY)

5/13/2019
(Street)

SOUTH SAN FRANCISCO, CA 94080
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   5/13/2019     C    1623336   (1) A   (2) 1623336   I   By Blue Devil Trust dated 12/03/2010   (3)
Common Stock   5/13/2019     C    301829   A   (2) 301829   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series A Redeemable Convertible Preferred Stock     (2) 5/13/2019     C         699280      (2)   (2) Common Stock   699280   $0.00   0   I   By Blue Devil Trust dated 12/03/2010   (3)
Series A Redeemable Convertible Preferred Stock     (2) 5/13/2019     C         301829      (2)   (2) Common Stock   301829   $0.00   0   D    
Series B Redeemable Convertible Preferred Stock     (2) 5/13/2019     C         924056      (2)   (2) Common Stock   924056   $0.00   0   I   By Blue Devil Trust dated 12/03/2010   (3)

Explanation of Responses:
(1)  The total represents shares received upon conversion of shares of Series A Redeemable Convertible Preferred Stock and shares of Series B Redeemable Convertible Preferred Stock.
(2)  Each share of Series A Redeemable Convertible Preferred Stock and each share of Series B Redeemable Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock, respectively, for no additional consideration at the completion of the Issuer's initial public offering. The Redeemable Convertible Preferred Stock had no expiration date.
(3)  Mr. Lamond is the trustee of the Blue Devil Trust dated 12/03/2010, and holds sole voting and dispositive power with respect to the shares held of record by Blue Devil Trust dated 12/03/2010.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Lamond David
C/O CORTEXYME, INC.
269 EAST GRAND AVE.
SOUTH SAN FRANCISCO, CA 94080 		X



Signatures
/s/ Christopher Lowe, as Attorney-in-Fact for David Lamond 5/13/2019
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Quince Therapeutics Charts.
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Quince Therapeutics Charts.